Overview The Ministry of Health and Family Welfare and the CDSCO have announced a series of regulatory reforms in 2026 aimed at simplifying drug‑manufacturing approvals, expediting clinical testing, and strengthening post‑market surveillance. Key Developments (2026) 25 Feb 2026 – Issuance of a Guidance Document for dossier‑based licensing of drugs. 23 Feb 2026 – Circular to fast‑track approvals for new drugs by granting immediate NOCs for laboratory testing. 21 Jan 2026 – Replacement of prior permission with an online intimation mechanism for BA/BE studies of export‑bound drugs. 02 Jan 2026 – Release of Indian Pharmacopoeia 2026 incorporating new vaccines, anti‑TB medicines and blood products. Alignment of the validity of Free Sale Certificates with manufacturing licences. July 2024 circular – Acceptance of pre‑existing pre‑clinical toxicity data to minimise animal testing. Delegation of certain powers under the Drugs and Cosmetics Act to senior CDSCO officers for quicker decision‑making. Launch of digital platforms: ONDLS and SUGAM Labs . Important Facts & Actions Since December 2022, CDSCO and State Drug Controllers have conducted risk‑based inspections of over 960 manufacturing premises, resulting in more than 860 regulatory actions such as show‑cause notices, suspension or cancellation of licences. Additionally, audits covered 1,100 cough‑syrup manufacturers and 380 blood centres, complemented by intensified market‑surveillance sampling. The centrally sponsored SSDRS scheme has released ₹756 crore, leading to the construction of 19 new and upgrade of 28 existing state drug‑testing laboratories. For post‑market safety, the PvPI National Coordination Centre at the Indian Pharmacopoeia Commission collates adverse event reports from monitoring centres and forwards safety recommendations to CDSCO. UPSC Relevance These reforms illustrate the government's push for a more efficient regulatory ecosystem, a topic relevant to GS III – Health & Family Welfare . Understanding the shift to dossier‑based licensing, the role of digital portals, and the emphasis on reducing animal testing helps answer questions on policy measures for innovation, public‑health safety, and regulatory governance. The alignment of export certifications and the SSDRS scheme also intersect with GS II – International Relations & Trade , highlighting India's effort to boost pharmaceutical exports. Way Forward Monitor the impact of dossier‑based licensing on drug‑launch timelines and domestic R&D investment. Assess how the online intimation mechanism influences export competitiveness, especially for generic manufacturers. Evaluate the effectiveness of risk‑based inspections and PvPI in enhancing drug safety post‑approval. Encourage further integration of state labs with ONDLS and SUGAM to achieve uniform standards across the country.